The liposomal encapsulation protects glutathione from degradation in the digestive system and improves its cellular uptake, resulting in significantly higher bioavailability compared to non-liposomal glutathione supplements
It activates two receptors: GLP-1 (glucagon-like peptide-1) GIP (glucose-dependent insulinotropic polypeptide) Both receptors are part of the body's incretin system
Some people may notice improvements in energy and well-being within days, while others may require several weeks of consistent treatment
In addition, because Rhesus-related hemolytic disease of the newborn (HDN) is disappearing thanks to the implementation of appropriate prophylaxis, one can expect G6PD-related NNJ to be generally on the increase, at least in relative terms
Other comparisons revealed smaller but still meaningful reductions: 33% lower risk versus metformin, 20% lower versus similar drugs in semaglutides class, and reductions ranging from 22% to 36% compared to other diabetes treatments